In preclinical trials, FP-1039 blocked FGF2-stimulated tumor cell proliferation and inhibited tumor growth in xenograft models.672 In phase I clinical trials, associated with paclitaxel and carboplatin, or docetaxel, intraperitoneal injection of FP-1039 was well tolerated in patients with solid malignancies.725 However, FP-1039 does not effectively inhibit endocrine FGFs (FGF19, FGF21, and FGF23).726 Therefore, FP-1039 has the potential to effectively block the neoplasms or advanced cancer-promoting FGFs, with less toxicity compared to small molecules such as FGFR kinase inhibitor. Here, FGF23 is linked to neoplasm.